Harada Kazuto, Mizrak Kaya Dilsa, Baba Hideo, Ajani Jaffer A
Department of Gastrointestinal Medical Oncology, University of Texas MD Anderson Cancer Center, Holcombe Boulevard, Texas, USA.
Department of Gastroenterological Surgery, Kumamoto University, Jonjo, Kumamoto, Japan.
F1000Res. 2017 Apr 18;6:501. doi: 10.12688/f1000research.10794.1. eCollection 2017.
Esophageal cancer is an aggressive malignancy with increasing incidence, and the prognosis of patients treated by surgery alone remains dismal. Preoperative treatment can modestly prolong overall survival. Preoperative chemotherapy or chemoradiation is the standard of care for resectable esophageal cancer (greater than clinical stage I and less than clinical stage IV). One of the challenges is to predict complete response in the surgical specimen from preoperative therapy and to avoid surgery in some patients but also predict ineffectiveness of preoperative therapy if the tumor is resistant and avoid such therapies altogether. In-depth understanding of the molecular biology could lead to personalized therapy, and in the future, clinical trials designed according to molecular features are expected. Here, we summarize preoperative treatment for esophageal adenocarcinoma and their potential.
食管癌是一种侵袭性恶性肿瘤，发病率不断上升，仅接受手术治疗的患者预后仍然很差。术前治疗可适度延长总生存期。术前化疗或放化疗是可切除食管癌（大于临床I期且小于临床IV期）的标准治疗方法。其中一个挑战是预测术前治疗在手术标本中的完全缓解情况，在一些患者中避免手术，但如果肿瘤耐药，也要预测术前治疗的无效性并完全避免此类治疗。深入了解分子生物学可能会带来个性化治疗，未来有望开展根据分子特征设计的临床试验。在此，我们总结了食管腺癌的术前治疗及其潜力。
